Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ATP4A | P20648 | 2/20 | 0.44 |
| ▸ | ATP4B | P51164 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733692 | 0.83 | ADORA3 (0.49) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL1734398 | 0.83 | CHRNA7 (0.49) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL1733451 | 0.82 | HPGD (0.61) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL1733437 | 0.81 | ADORA3 (0.44) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL1734511 | 0.80 | KDM4E (0.66) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL30755408 | 0.78 | ALDH1A1 (0.61) | HSP90AA1ADORA3HSP90AB1ADORA1IKBKB | |
| SCHEMBL1734273 | 0.78 | ALDH1A1 (0.65) | ADORA3ADORA2AHPGDALDH1A1KDM4E | |
| SCHEMBL1734495 | 0.78 | KDM4E (0.51) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A | |
| SCHEMBL2816890 | 0.78 | HSP90AA1 (0.63) | HSP90AA1ADORA3HSP90AB1ADORA2AHPGD | |
| SCHEMBL1734652 | 0.76 | VCP (0.46) | HSP90AA1ADORA3HSP90AB1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038516-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-02-05 | — | — | US | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2212297-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009047359-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249149-A1 | Inhibitors of Protein Kinases | CDK9, CDK19, CDK2 | HSP90AA1 1225/4885ADORA3 4596/4885HSP90AB1 1092/4885 |
| US-20150038516-A1 | Inhibitors of Protein Kinases | CDK1, CDK2, CCNK | HSP90AA1 779/4885ADORA3 2060/4885HSP90AB1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.